|
CALGARY, May 22 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has successfully transferred cGMP production for REOLYSIN(R) at the 40-litre batch size to SAFC Pharma(TM), a Division of Sigma-Aldrich Corporation.
PARSIPPANY, NJ, May 22 / MARKET WIRE/ -- Solara, a CommonHealth business unit created to provide strategic marketing services to improve patient access to pharmaceutical brands competing in managed markets, today announced the hiring of Yana Volman as an account supervisor. CommonHealth...
SAN DEIGO--(BUSINESS WIRE)--Commonwealth Biotechnologies, Inc. (“CBI”) (NASDAQ Capital Market:CBTE) today provided a management discussion of its first quarter 2008 financial results and a progress update on Venturepharm (Asia), CBI’s joint venture with Venturepharm Laboratories Ltd (“VPL”)...
Posted on: Thursday, 22 May 2008, 09:01 CDT Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that data from various Phase I and Phase II clinical trials of Cougar's lead drug candidate CB7630 (abiraterone acetate) will be presented during the 44th Annual Meeting of the American Society of...
Posted on: Thursday, 22 May 2008, 09:01 CDT Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading...
By MEGAN ROLLAND NYT REGIONAL NEWSPAPERS ALACHUA | A multimillion-dollar industry is blossoming in the city of Alachua, leaving nearby communities eager for a piece of the action. Biotechnology - which uses living organisms to solve problems in areas such as agriculture, food sciences and...
Laupheim, Germany - Rentschler Biotechnologie and Boehringer Ingelheim, both leading companies in biopharmaceutical development and production, have signed a preferred partnership agreement. The cooperation will enable Rentschler Biotechnologie's clients to gain access to Boehringer Ingelheim's...
Amarin Corporation plc today announced that it has closed the $30 million first tranche of its previously announced $60 million private placement. The net proceeds of the first tranche, after deducting the placement agents' fees and estimated offering expenses, will be approximately $27 million.
SAN MARINO, Calif., May 22 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast cancer that is refractory to conventional chemotherapy (J Clin Oncol 26:14509, 2008). This clinical...
KS Jayaraman, one of India's most well known science journalists (now with "Nature"), has written a very interesting piece on biotech patents and the prospects of compulsory licensing in developing countries such as India, Brazil and Thailand. Apart from two minor mistakes (he assumes that...
